Clinical Trial

Clinical Trial - most related articles:

- Single PILL may prevent heart disease - 3.1
- Breast cancer drug Abraxane promising for malignant melanoma treatment - 2.7
- Clinical trial of human embryonic stem cell therapy in US - 2.7
- Single radiation to treat breast cancer - 2.5
- $9 million grant for prostate cancer research - 2.5
- Lupus drug Benlysta effective for SLE patients - 2.5
- Progesterone for traumatic brain injury tested - 2.4
- Champion clinical trial program of cangrelor discontinued - 2.4
- PRO 2000 anti HIV gel is ineffective - 2.4
- Vaccine to help people quit smoking - 2.4

Clinical Trial articles

Brain cancer vaccine prepared from brain tumor proves effective
A new brain cancer vaccine tailored to individual patients by using material from their own tumors has proven effective in a multicenter phase 2 clinical trial at extending their lives by several months or longer. The patients suffered from recurrent glioblastoma multiforme-which kills thousands of Americans every year.

Heart failure patients may get benefit from testosterone supplements
Testosterone supplements helped heart failure patients breathe better and exercise more. This new research analyzed four randomized clinical trials of patients with moderate to severe chronic heart failure. Patients were given commercial testosterone supplements by injection, patch or gel.

Alzheimer's Disease patients may not get benefit from antioxidants
An antioxidant combination of vitamin E, vitamin C and a-lipoic acid (E/C/ALA) was not associated with changes in some cerebrospinal fluid biomarkers related to Alzheimer disease in a randomized controlled trial, revealed by researchers.

New cancer drug development institute at UT MD Anderson
Academic and government leaders announced the establishment of a major new research institute at The University of Texas MD Anderson Cancer Center that will blend the best attributes of academic and industrial research to identify and validate new cancer targets, convert such scientific knowledge into new cancer drugs, and advance these novel agents into innovative clinical trials.

CCSVI role in multiple sclerosis seems to be controversial
Chronic cerebrospinal venous insufficiency (CCSVI) appears to be more common in people with multiple sclerosis than in people without the condition, states a review of published studies in CMAJ (Canadian Medical Association Journal).However, there are not enough high-quality studies to allow definitive conclusions.

Expandable prosthesis resolves advanced aortic valve disease
Among individuals 65 years and older, as many as 30 percent have aortic valve sclerosis or stenosis and as a result of their deteriorating health, they cannot enjoy a normal lifestyle.

Stroke clinical trial finds intensive medical treatment better than brain stent
Patients at a high risk for a second stroke who received intensive medical treatment had fewer strokes and deaths than patients who received a brain stent in addition to the medical treatment, a large nationwide clinical trial has shown.

Lithium may prevent brain damage in patients with Parkinson's disease
Researcher are focusing on lithium as a potential treatment for Parkinson's disease -- PD -- as well as its efficacy in combination with drugs currently used to control the symptoms of the disease. Lithium profoundly prevents the aggregation of toxic proteins and cell loss associated with Parkinson's disease (PD) in a mouse model of the condition.

Ovarian cancer screening does not improve survival
In a clinical trial that included nearly 80,000 women, those who received ovarian cancer screening did not have a reduced risk of death from ovarian cancer compared to women who received usual care, but did have an increase in invasive medical procedures and associated harms as a result of being screened.

Pfizer drug reduces breast cancer in high risk women
The drug exemestane significantly reduces the risk of breast cancer in high-risk, postmenopausal women is the result of an international, randomized double-blind phase III clinical trial in which University at Buffalo researchers and hundreds of Western New York women played a critical role, revealed at the American Society of Clinical Oncology annual meeting.

Niacin and statin treatment did not protect heart
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped a clinical trial studying a blood lipid treatment 18 months earlier than planned.

New class of cancer drugs could work in colon cancers with genetic mutation
A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds.

Omalizumab relieves seasonal asthma attacks in youth
A drug that targets the antibody immunoglobulin E (IgE), a key player in asthma, nearly eliminated seasonal increases in asthma attacks and decreased asthma symptoms among young people living in inner city environments, a clinical trial sponsored by the National Institutes of Health has found.

International clinical trial tests targeted drug for melanoma skin cancer
Rush University Medical Center has just enrolled the first U.S. patient in an international clinical trial testing a novel drug to treat certain kinds of melanoma, a deadly skin cancer that in its advanced stages currently has few effective treatments.

US company starts clinical trial using stem cells to treat macular degeneration
Advanced Cell Technology, Inc. ("ACT"; OTCBB:ACTC) announced that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world.

Clinical trial of human embryonic stem cell therapy in US
Geron Corporation (Nasdaq: GERN) announced the enrollment of the first patient in the company's clinical trial of human embryonic stem cell (hESC)-derived oligodendrocyte progenitor cells, GRNOPC1.

Artificial pancreas successfully controls blood sugar more than 24 hours
An artificial pancreas system that closely mimics the body's blood sugar control mechanism was able to maintain near-normal glucose levels without causing hypoglycemia in a small group of patients.

Pneumococcal vaccine offers protection to HIV infected
A clinical trial of a vaccine against a major cause of pneumonia and meningitis has shown that it can prevent three out of four cases of re-infection in HIV-infected adults in Africa.

Ethosuximide is preferred for childhood epilepsy
The first comprehensive comparative effectiveness clinical trial of three widely used anti-seizure drugs for childhood absence epilepsy – the most common form of epilepsy in kids – has established an evidence-based approach for initial drug therapy.

Progesterone for traumatic brain injury tested
Researchers at 17 medical centers across the US soon will begin using the hormone progesterone to treat patients who experience traumatic brain injury (TBI).

New safety controls for asthma drugs, US
The U.S. Food and Drug Administration announced that drugs in the class of long-acting beta agonists (LABAs) should never be used alone in the treatment of asthma in children or adults.

Testing gene therapy for Alzheimer's disease
University Hospitals Case Medical Center is one of 12 sites conducting the first Phase 2 clinical trial of a gene therapy for Alzheimer's disease (AD). The study uses a viral-based gene transfer system called CERE-110, which is designed to deliver nerve growth factor (NGF) into the brain.

PRO 2000 anti HIV gel is ineffective
Pro 2000, a vaginal microbicide gel designed to reduce women's risk of HIV infection, showed no evidence that it reduces the risk of HIV infection, revealed by researchers at Britain's Medical Research Council (MRC).

New 3 drug combination for multiple myeloma patients
A new three-drug combination has shown in a phase 1/2 clinical trial that it is a "highly effective regimen" in the treatment of patients newly diagnosed with multiple myeloma, a cancer of white blood cells in bone marrow, say researchers from Dana-Farber Cancer Institute.

New HIV vaccine safe and effective in preventing HIV infection
In an encouraging development, an investigational vaccine regimen has been shown to be well-tolerated and to have a modest effect in preventing HIV infection in a clinical trial involving more than 16,000 adult participants in Thailand.

2009 H1N1 influenza vaccines in healthy adults - early results
There are encouraging reports emerging from various clinical trials of 2009 H1N1 influenza vaccines, conducted by various vaccine manufacturers. Additional companies are expected to announce their preliminary trial results shortly.

A new therapy to cure skin cancer
A potential new investigational therapy for advanced and metastatic basal cell skin cancer is revealed by researchers.

Mediterranean diet and exercise lower Alzheimer's disease risk
Both being more physically active and adhering to a Mediterranean-type diet appears to be associated with reduced Alzheimer's risk, according to a new report in the August 12, 2009 issue of the Journal of the American Medical Association (JAMA).

US to launch clinical trials to test 2009 H1N1 influenza vaccine
Scientists in a network of medical research institutions across the United States are set to begin a series of clinical trials to gather critical data about influenza vaccines, including two candidate H1N1 flu vaccines.

Breast cancer drug Abraxane promising for malignant melanoma treatment
An approved breast-cancer drug nab-paclitaxel, trade named Abraxane, has been found promising in clinical trial for the treatment of metastatic malignant melanoma, revealed by researchers.

New consensus on using APBI to treat breast cancer
A new consensus statement outlining patient selection criteria and best practices for the use of accelerated partial breast irradiation (APBI) outside the context of a clinical trial has been published in the July 15 issue of the International Journal of Radiation Oncology Biology Physics.

Takeda's diabetes drug alogliptin received FDA's objection
US top most health agency FDA has asked Takeda to conduct an additional clinical trial to rule out any adverse effects of alogliptin in relation to heart, that means Takeda needs to conduct a cardiovascular safety trial for alogliptin.

Rheumatoid arthritis drug masitinib found effective
A clinical trial of masitinib, a drug in development for the treatment of rheumatoid arthritis, has shown it to be well tolerated and effective, revealed by researchers in BioMed Central's journal Arthritis Research and Therapy.

Success with ipilimumab in prostate cancer patients
Two Mayo Clinic patients whose prostate cancer had been considered inoperable are now cancer free thanks in part to an experimental drug therapy that was used in combination with standardized hormone treatment and radiation therapy.

Option Inferior Vena Cava Filter gets FDA clearance in US
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Option(TM) Inferior Vena Cava (IVC) Filter in the United States, for use in both permanent and retrievable indications.

Avandia has no increased overall heart risk
Clinical trial results presented at the American Diabetes Association annual meeting show that overall rates of cardiovascular hospitalization and cardiovascular death are similar in patients taking Avandia (rosiglitazone) compared to those receiving metformin and sulfonylurea.

Merck's heart failure drug rolofylline failed
Merck's experimental heart failure drug rolofylline failed to meet the goals in a clinical trial, failing to improve patients. Merck won't seek approval this year for this heart failure drug rolofylline after preliminary results.

Positive clinical trial results of vilazodone for depression
Clinical Data, Inc. (NASDAQ: CLDA) announced positive top-line results from the second of two Phase III trials of its investigational compound, vilazodone, for the treatment of major depressive disorder (MDD).

Breast cancer gene responds to blood pressure drug in lab
Researchers have identified a gene that is overexpressed in up to 20 percent of breast cancers and that could be blocked in the lab by a currently available blood pressure drug, according to a new study from the University of Michigan Comprehensive Cancer Center.

Green tea shows promise in leukemia
Mayo Clinic researchers are reporting positive results in early leukemia clinical trials using the chemical epigallocatechin gallate (EGCG), an active ingredient in green tea.

$24 million for rare and neglected diseases research
The National Institutes of Health is launching the first integrated, drug development pipeline to produce new treatments for rare and neglected diseases. The $24 million program jumpstarts a trans-NIH initiative called the Therapeutics for Rare and Neglected Diseases Program, or TRND.

Champion clinical trial program of cangrelor discontinued
The Medicines Company (NASDAQ: MDCO) announced that it is discontinuing its Phase 3 CHAMPION clinical trial program of cangrelor in patients undergoing percutaneous coronary intervention (PCI).

Herpes medication does not reduce HIV transmission risk
A recently completed international multi-center clinical trial has found that acyclovir, a drug widely used as a safe and effective treatment to suppress herpes simplex virus-2 (HSV-2), which is the most common cause of genital herpes, does not reduce the risk of HIV transmission when taken by people infected with both HIV and HSV-2.

New drug aims to transform malaria treatment
Ranbaxy Laboratories Limited (Ranbaxy) announced the commencement of Phase-III clinical trials for its new Anti-malaria combination drug, Arterolane maleate + Piperaquine phosphate in India, Bangladesh and Thailand.

Anti aging cosmetic reduces wrinkles
Scientists testing a cosmetic anti-ageing product sold on the high street have shown it can clinically reduce wrinkles and improve the appearance of skin damaged by everyday exposure to sunlight.

Boosting immune response to destroy tumours
Researchers have discovered how to trigger an improved immune response to cancer that could be included in new clinical trials that use a patient's own cells to destroy tumours.

New iPhone app allows search of all registered clinical trials
Before today, searching for one of more than 71,500 clinical trials in the National Library of Medicine and National Institutes of Health database required a chair, computer, internet connection, and a session on the government's clinical trials website.

Positive results of Albuferon in Chronic Hepatitis C
Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that Albuferon (albinterferon alfa-2b) met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) in ACHIEVE 1, a Phase 3 clinical trial of Albuferon in combination with ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C (p=0.0008).

Microbicide promising as HIV prevention method for women
A clinical trial involving more than 3,000 women in the U.S. and southern Africa demonstrates for the first time the promise of a vaginal microbicide gel for preventing HIV infection in women.

Advice for treatment of cough, colds in children under 6
Responding to guidance issued by the Medicines and Healthcare products Regulatory Agency (MHRA), advising that cough and cold treatments should not be used for children under 6 years of age, the Royal Pharmaceutical Society of Great Britain (RPSGB) has issued the following advice to parents.

Clinical trials overseas raises quality control issues
Top-tier U.S.-based pharmaceutical companies are moving their clinical trials overseas at warp speed, raising questions about ethics, quality control, and even the scientific value of their findings for people back in the U.S.

Multivitamins offer no benefit in postmenopausal women
The largest study ever conducted on postmenopausal women shows that multivitamins may offer no benefit in reducing the risk of common cancers, cardiovascular disease or overall mortality.

ViroPharma's Maribavir failed in bone marrow transplant patients
ViroPharma Incorporated (Nasdaq: VPHM) announced that its Phase 3 trial evaluating maribavir used as prophylaxis in allogeneic stem cell, or bone marrow, transplant (SCT) patients did not achieve its primary endpoint.

Anti HIV gel shows promise in preventing HIV infection in women
An investigational vaginal gel intended to prevent HIV infection in women has demonstrated encouraging signs of success in a clinical trial conducted in Africa and the United States.

Weight loss reduces urinary incontinence in overweight obese women
Reducing urinary incontinence can now be added to the extensive list of health benefits of weight loss, according to a clinical trial funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Office of Research on Women's Health (ORWH), both part of the National Institutes of Health (NIH).

Human clinical trial of embryonic stem cell therapy approved
Geron Corporation (Nasdaq: GERN) announced that the U.S. Food and Drug Administration (FDA) has granted clearance of the company's Investigational New Drug (IND) application for the clinical trial of GRNOPC1 in patients with acute spinal cord injury.

Postnatal depression can be prevented
Health visitors can be trained to identify women with postnatal depression and offer effective treatment, while telephone peer support (mother to mother) may halve the risk of developing postnatal depression, suggests research published on bmj.com.

Healthy diet may cut risk of breast cancer recurrence
A secondary analysis of a large, multicenter clinical trial has shown that a diet loaded with fruits, vegetables and fiber and somewhat lower in fat compared to standard federal dietary recommendations cuts the risk of recurrence in a subgroup of early-stage breast cancer survivors – women who didn't have hot flashes – by approximately 31 percent.

Hepatitis C declines health with liver disease
An NIH funded multi-center clinical trial found no benefit from "maintenance therapy," low-dose peginterferon used for hepatitis C patients who have not responded to an initial round of treatment.

New drug tasimelteon for jet lag
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) reports publication in The Lancet, one of the world's leading medical journals, results of clinical trials of its novel circadian regulator, experimental compound tasimelteon (VEC-162).

Single PILL may prevent heart disease
A new clinical trial looking at a single pill to prevent cardiovascular disease is starting in Auckland, New Zealand.

Acomplia rimonabant obesity drug withdrawn
Sanofi-aventis announced that the European Medicines Agency (EMEA) has recommended to the European Commission (EC) the temporary suspension of the marketing authorisation of Acomplia(R) (rimonabant) for the approved indication of overweight and obese patients.

Live cell therapy clinical trial in New Zealand for diabetics
Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) announced that New Zealand Health Minister, the Honorable David Cunliffe, has approved an application from the company to conduct in New Zealand a Phase I/IIa clinical trial of DiabeCell®, LCT's lead product candidate for the treatment of insulin dependent (Type 1) diabetes.

Vitamin B does not slow cognitive decline in Alzheimer's disease
A clinical trial led by Paul S. Aisen, M.D., professor of neurosciences at the University of California, San Diego School of Medicine, showed that high-dose vitamin B supplements did not slow the rate of cognitive decline in patients with mild to moderate Alzheimer disease.

Trials supporting FDA approved drugs remained unpublished
Over half of all supporting trials for FDA-approved drugs remained unpublished 5 years after approval, says new research published in this week's PLoS Medicine. The most important trials determining efficacy, and those with statistically significant results and larger sample sizes, are more likely to be published.

India to develop HIV AIDS vaccine soon
A second Phase I AIDS vaccine clinical trial in India was successfully completed, the Indian Council of Medical Research, the National AIDS Control Organization and the International AIDS Vaccine Initiative announced.

GSK statement on MHRA Seroxat investigation
GlaxoSmithKline (GSK) notes the conclusions announced by the Medicines and Healthcare products Regulatory Agency (MHRA) regarding its investigation into disclosure of paediatric trial data for the anti-depressant medicine Seroxat (paroxetine).

Tenofovir gel safe for daily use
A vag inal microbicide that incorporates an antiretroviral (ARV) drug normally used to treat people with HIV is safe for sexually active HIV-negative women to use every day over an extended period, suggest results of a clinical trial of tenofovir topical gel.

Stem cell therapy trials to mend shattered bones
Scientists are developing a revolutionary way to mend damaged bones and cartilage using a patient's own stem cells.

Laser to detect potential diseases via breath
By blasting a person's breath with laser light, scientists from the National Institute of Standards and Technology and the University of Colorado at Boulder have shown that they can detect molecules that may be markers for diseases like asthma or cancer.

Cholesterol lowering drug may fight staph infection
An international team of researchers supported by the National Institutes of Health (NIH) has blocked staph infections in mice using a drug previously tested in clinical trials as a cholesterol-lowering agent. The novel approach, described in the February 14 online edition of Science, could offer a new direction for therapies against a bacterium that's becoming increasingly resistant to antibiotics.

$9 million grant for prostate cancer research
Henry Ford Hospital is embarking on an expanded major clinical trial involving the use of gene therapy in combination with radiation therapy, to determine if the combined treatment is more effective than radiation therapy alone for patients with intermediate risk prostate cancer.

Intensive blood glucose lowering treatment proved fatal for diabetes patients
Intensive blood glucose lowering treatment proved fatal for diabetes patients in a US study, and for Safety, National Heart, Lung, and Blood Institute (NHLBI) has changed intensive blood sugar treatment strategy in clinical trial of diabetes and cardiovascular disease.

GVAX cancer immunotherapy improves prostate cancer survival
Cell Genesys, Inc. (Nasdaq: CEGE) announced that the Independent Data Monitoring Committee (IDMC) for VITAL-1, the first of two ongoing Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, has completed a pre-planned interim analysis and has recommended that the study continue, as GVAX cancer immunotherapy improves prostate cancer patients survival.

Selective reporting of antidepressant trials may have adverse consequences
Selective publication in reporting results of antidepressant trials exaggerates the effectiveness of the drugs, and may have adverse consequences for researchers, study participants, health care professionals, and patients, revealed in a new study.

American physicians prescribe placebos on occasion
In the first study examining American physicians' use of placebos in clinical practice in the 21st Century, 45 percent of Chicago internists report they have used a placebo at some time during their clinical practice researchers report in the January issue of Journal of General Internal Medicine.

Potential drugs for mental retardation and autism treatment
Researchers at MIT's Picower Institute for Learning and Memory have corrected key symptoms of mental retardation and autism in mice. The work, which will be reported in the Dec. 20 issue of Neuron, indicates that a certain class of drugs could have the same effect in humans. These drugs are not yet approved by the FDA, but will soon be entering into clinical trials.

Asacol found effective in ulcerative colitis, proctitis
Data from two Phase III clinical trials support that Asacol, an oral, non-steroidal medication that belongs to the class of agents known as 5-aminosalicylic acids (5-ASAs), is an effective and well-tolerated treatment for patients with all extents of ulcerative colitis (UC), including isolated proctitis.

Predicting hip fracture risk in postmenopausal women
To help doctors predict the five-year risk of hip fractures in their postmenopausal patients, a team of UC Davis researchers has developed a method that assesses nearly a dozen factors, including age, ethnicity and level of physical activity.

79 Clinical Trial articles listed above.

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
3.4